Smoking cessation (also known as quitting smoking or simply quitting) is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. Nicotine withdrawal makes the process of quitting often difficult.
Seventy percent of smokers would like to quit smoking, and 50 percent report attempting to quit within the past year. Smoking is the leading preventable cause of death worldwide. Tobacco cessation significantly reduces the risk of dying from tobacco-related diseases such as coronary heart disease, chronic obstructive pulmonary disease (COPD), and lung cancer. Due to its link to many chronic diseases, cigarette smoking has been restricted in many public areas.
Many different strategies can be used for smoking cessation, including abruptly quitting without assistance ("cold turkey"), cutting down then quitting, behavioral counseling, and medications such as bupropion, cytisine, nicotine replacement therapy, or varenicline. Most smokers who try to quit do so without assistance, though only 3% to 6% of quit attempts without assistance are successful long-term. Behavioral counseling and medications each increase the rate of successfully quitting smoking, and a combination of behavioral counseling with a medication such as bupropion is more effective than either intervention alone. A meta-analysis from 2018, conducted on 61 RCT, showed that one year after people quit smoking with the assistance of first line smoking cessation medications (and some behavioral help), only approximately 20% of them sustained abstinent, as compared to around 12% who did not take medication.
In nicotine-dependent smokers, quitting smoking can lead to symptoms of nicotine withdrawal such as nicotine cravings, anxiety, irritability, depression, and weight gain.:2298 Professional smoking cessation support methods generally attempt to address nicotine withdrawal symptoms to help the client break free of nicotine addiction.
1.3Cut down to quit
1.4Set a Quit Plan and Quit Date
1.6.3Competitions and incentives
1.8Substitutes for cigarettes
2.1Children and adolescents
2.7Homeless and poverty
2.8People living with HIV/AIDS
3Comparison of success rates
4Factors affecting success
Major reviews of the scientific literature on smoking cessation include:
Systematic reviews of the Cochrane Tobacco Addiction Group of the Cochrane Collaboration. As of 2016, this independent, international, not-for-profit organization has published over 91 systematic reviews "on interventions to prevent and treat tobacco addiction" which will be referred to as "Cochrane reviews" in this article.
Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update of the United States Department of Health and Human Services, which will be referred to as the "2008 Guideline." The Guideline was originally published in 1996 and revised in 2000. For the 2008 Guideline, experts screened over 8,700 research articles published between 1975 and 2007.:13–14 More than 300 studies were used in meta-analyses of relevant treatments; an additional 600 reports were not included in meta-analyses, but helped formulate the recommendations.:22 Limitations of the 2008 Guideline include not evaluating studies of "cold turkey" methods ("unaided quit attempts") and its focus on studies that followed up subjects only to about 6 months after the "quit date" in order to capture the greatest number of studies for analyses. Most relapses occur early in a quit attempt, though some relapses can occur later - even years later.
It is common for ex-smokers to have made a number of attempts (often using different approaches on each occasion) to stop smoking before achieving long-term abstinence. According to a recent survey from UNC over 74.7% of smokers attempt to quit without any assistance, otherwise known as "Cold Turkey", or with home remedies. A recent study estimated that ex-smokers make between 6 and 30 attempts before successfully quitting. Identifying which approach or technique is eventually most successful is difficult; it has been estimated, for example, that only about 4% to 7% of people are able to quit smoking on any given attempt without medicines or other help. A recent review of unassisted quit attempts in 9 countries found that the majority of quit attempts are still unassisted, though the trend seems to be shifting. In the U.S., for example, the rate of unassisted quitting fell from 91.8% in 1986 to 52.1% during 2006 to 2009. The most frequent unassisted methods were "cold turkey", a term that has been used to mean either unassisted quitting or abrupt quitting  and "gradually decreased number" of cigarettes, or "cigarette reduction".
"Cold turkey" is a colloquial term indicating abrupt withdrawal from an addictive drug, and in this context indicates sudden and complete cessation of all nicotine use. In three studies, it was the quitting method cited by 76%, 85%, or 88% of long-term successful quitters. In a large British study of ex-smokers in the 1980s, before the advent of pharmacotherapy, 53% of the ex-smokers said that it was "not at all difficult" to stop, 27% said it was "fairly difficult", and the remaining 20% found it very difficult. Studies have found that two-thirds of recent quitters reported using the cold turkey method and found it helpful.
A 21mg dose nicotine patch applied to the left arm.
The American Cancer Society notes that "Studies in medical journals have reported that about 25% of smokers who use medicines can stay smoke-free for over 6 months." Single medications include:
Nicotine replacement therapy (NRT): Five medications have been approved by the U.S. Food and Drug Administration (FDA) deliver nicotine in a form that does not involve the risks of smoking: transdermal nicotine patches, nicotine gum, nicotine lozenges, nicotine spray, and nicotine inhalers. High quality evidence indicates that these forms of NRT improve the success rate for people who attempt to stop smoking. NRTs are meant to be used for a short period of time and should be tapered down to a low dose before stopping. NRTs increase the chance of stopping smoking by 50 to 60% compared to placebo or to no treatment. There are no side effects reported other than local slight irritation and rarely non-ischemic chest pain.
Further increased chance of success was found when a combination of the nicotine patch and a faster acting form was used. A study found that 93% of over-the-counter NRT users relapse and return to smoking within six months.
There is weak evidence that adding mecamylamine to nicotine is more effective than nicotine alone.
Antidepressants: The antidepressant bupropion is considered a first-line medication for smoking cessation and has been shown in many studies to increase long-term success rates. People who take bupropion should be monitored for any unusual mood changes; bupropion also increases the risk of seizures and should not be used in people with a seizure disorder. Nortriptyline has also been shown to increase smoking cessation success rates. In a recent Cochrane update, Nortriptyline did not produce significant rates of abstinence versus placebo, nor evidence of additional benefit when combined with NRT, although only four trials were included in the analysis.
Other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and St. John's wort have not been consistently shown to be effective for smoking cessation.
Varenicline decreases the urge to smoke and reduces withdrawal symptoms and is therefore considered a first-line medication for smoking cessation. A 2016 Cochrane review of 27 studies also found that the number of people stopping smoking with varenicline was higher than with bupropion or NRT. Varenicline more than doubled the chances of quitting compared to placebo, and was also as effective as combining two types of NRT. 2 mg/day of varenicline has been found to lead to the highest abstinence rate (33.2%) of any single therapy, while 1 mg/day leads to an abstinence rate of 25.4%. A 2011 review of double-blind studies found that varenicline has increased risk of serious adverse cardiovascular events compared with placebo. It is presently unclear if varenicline causes cardiovascular events or if it makes them worse. Concerns arose that varenicline may cause neuropsychiatric side effects, including suicidal thoughts and behavior. However, more recent studies indicate less serious neuropsychiatric side effects. For example, a 2016 study involving 8,144 patients treated at 140 centers in 16 countries "did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo". A 2016 Cochrane review concluded that the most recent evidence does not indicate that there is a link between depressed moods, agitation or suicidal thinking in smokers taking varenicline to decrease the urge to smoke. For people who have pre-existing mental health difficulties, varenicline may slightly increase the risk of experiencing these neuropsychiatric adverse events.
Clonidine may reduce withdrawal symptoms and "approximately doubles abstinence rates when compared to a placebo," but its side effects include dry mouth and sedation, and abruptly stopping the drug can cause high blood pressure and other side effects.
There is no good evidence Anxiolytics are helpful.
Previously, rimonabant which is a cannabinoid type 1 receptor antagonist was used to help in quitting and to moderate the expected weight gain. But it is important to know that rimonabant and taranabant production is stopped by the manufacturers in 2008 due to its serious side effects.
The 2008 US Guideline specifies that three combinations of medications are effective::118–120
Long-term nicotine patch and ad libitum NRT gum or spray
Nicotine patch and nicotine inhaler
Nicotine patch and bupropion (the only combination that the US FDA has approved for smoking cessation)
A meta-analysis from 2018, conducted on 61 RCT, showed that during their first year of trying to quit, approximately 80% of the participants in the studies who got drug assistance (bupropion, NRT, or varenicline) returned to smoking while 20% continued to not smoke for the entire year (i.e.: remained sustained abstinent). In comparison, 12% the people who got placebo kept from smoking for (at least) an entire year. This makes the net benefit of the drug treatment to be 8% after the first 12 months. In other words, out of 100 people who will take medication, approximately 8 of them would remain non-smoking after one year thanks to the treatment. During the course of one year, the benefit from using smoking cessation medications (Bupropion, NRT, or Varenicline) decreases from 17% in 3 months, to 12% in 6 months to 8% in 12 months.
Cut down to quit
Gradual reduction involves slowly reducing one's daily intake of nicotine. This can theoretically be accomplished through repeated changes to cigarettes with lower levels of nicotine, by gradually reducing the number of cigarettes smoked each day, or by smoking only a fraction of a cigarette on each occasion. A 2009 systematic review by researchers at the University of Birmingham found that gradual nicotine replacement therapy could be effective in smoking cessation. There is no significant difference in quit rates between smokers who quit by gradual reduction or abrupt cessation as measured by abstinence from smoking of at least six months from the quit day, suggesting that people who want to quit can choose between these two methods.
Set a Quit Plan and Quit Date
Most smoking cessation resources such as the CDC and Mayo Clinic encourage smokers to create a quit plan, including setting a quit date, which helps them anticipate and plan ahead for smoking challenges. A quit plan can improve a smoker’s chance of a successful quit as can setting Monday as the quit date, given that research has shown that Monday more than any other day is when smokers are seeking information online to quit smoking and calling state quit lines.
A Cochrane review found evidence that community interventions using "multiple channels to provide reinforcement, support and norms for not smoking" had an effect on smoking cessation outcomes among adults. Specific methods used in the community to encourage smoking cessation among adults include:
Policies making workplaces and public places smoke-free. It is estimated that "comprehensive clean indoor laws" can increase smoking cessation rates by 12%–38%. In 2008, the New York State of Alcoholism and Substance Abuse Services banned smoking by patients, staff and volunteers at 1,300 addiction treatment centers.
Voluntary rules making homes smoke-free, which are thought to promote smoking cessation.
Initiatives to educate the public regarding the health effects of second-hand smoke, including the significant dangers of secondhand smoke infiltration for residents of multi-unit housing.
Increasing the price of tobacco products, for example by taxation. The US Task Force on Community Preventive Services found "strong scientific evidence" that this is effective in increasing tobacco use cessation :28–30 It is estimated that an increase in price of 10% will increase smoking cessation rates by 3–5%.
Mass media campaigns. The US Task Force on Community Preventive Services declared that "strong scientific evidence" existed for these when "combined with other interventions",:30–32 and a Cochrane review suggested their benefits with paying attention to their intensty and duration.
Institutional level smoking bans. A recent Cochrane Review found evidence that imposing bans at the institutional level (i.e. hospitals and prisons) reduced smoking rates and secondhand exposure, although the evidence base was rated as poor quality.
Great American Smokeout is an annual event that invites smokers to quit for one day, hoping they will be able to extend this forever.
The World Health Organization's World No Tobacco Day is held on May 31 each year.
Smoking-cessation support is often offered over the telephone quitlines (e.g., the US toll-free number 1-800-QUIT-NOW), or in person. Three meta-analyses have concluded that telephone cessation support is effective when compared with minimal or no counselling or self-help, and that telephone cessation support with medication is more effective than medication alone.,:91–92:40–42 and the intensive individual counselling is more effective than the brief individual counselling intervention. There is about 10% to 25% increase of the chance of smoking cessation success with the more behavioral support provided in person or via telephone when used as an adjunct to pharmacotherapy .
Online social cessation networks attempt to emulate offline group cessation models using purpose built web applications. They are designed to promote online social support and encouragement for smokers when (usually automatically calculated) milestones are reached. Early studies have shown social cessation to be especially effective with smokers aged 19–29.
Group or individual psychological support can help people who want to quit. Recently, group therapy has been found to be more helpful than self-help and some other individual intervention. The psychological support form of counselling can be effective alone; combining it with medication is more effective, and the number of sessions of support with medication correlates with effectiveness.:89–90,101–103 The counselling styles that have been effective in smoking cessation activities include motivational interviewing, cognitive behavioural therapy and Acceptance and Commitment Therapy, methods based on Cognitive Behavioral Therapy, as well as the CBQ (Cognitive Behavioral Quitting) method focusing on the psychological dependence on smoking.
The Freedom From Smoking group clinic includes eight sessions and features a step-by-step plan for quitting smoking. Each session is designed to help smokers gain control over their behavior. The clinic format encourages participants to work on the process and problems of quitting both individually and as part of a group.
Multiple formats of psychosocial interventions increase quit rates: 10.8% for no intervention, 15.1% for one format, 18.5% for 2 formats, and 23.2% for three or four formats.:91
The Transtheoretical Model including "stages of change" has been used in tailoring smoking cessation methods to individuals. However, a 2010 Cochrane review concluded that "stage-based self-help interventions (expert systems and/or tailored materials) and individual counselling were neither more nor less effective than their non-stage-based equivalents."
Some health organizations manage text messaging services to help people avoid smoking
According to the most recent Cochrane review in 2019, self-help materials may produce a small increase in quit rates specially when there is no other supporting intervention form. In the 2008 Guideline, "the effect of self-help was weak," and the number of types of self-help did not produce higher abstinence rates.:89–91 Nevertheless, self-help modalities for smoking cessation include:
In-person self-help groups such as Nicotine Anonymous, or web-based cessation resources such as Smokefree.gov, which offers various types of assistance including self-help materials.
WebMD: a resource providing health information, tools for managing health, and support.
Interactive web-based and stand-alone computer programs and online communities which assist participants in quitting. For example, "quit meters" keep track of statistics such as how long a person has remained abstinent. In the 2008 US Guideline, there was no meta-analysis of computerised interventions, but they were described as "highly promising.":93–94 A meta-analysis published in 2009, a Cochrane review updated in 2013,[needs update] and a 2011 systematic review found the evidence base for such interventions weak, although interactive and tailored interventions show some promise.
Mobile phone-based interventions: A 2016 updated Cochrane review stated that "the current evidence supports a beneficial impact of mobile phone-based cessation interventions on six-month cessation outcomes. A 2011 randomized trial of mobile phone-based smoking cessation support in the UK found that a Txt2Stop cessation program significantly improved cessation rates at 6 months. A 2013 meta-analysis also noted "modest benefits" of mobile health interventions.
Interactive web-based programs combined with a Mobile phone: Two RCTs documented long-term treatment effects (abstinence rate: 20-22 %) of such interventions,.
Self-help books such as Allen Carr's Easy Way to Stop Smoking.
Spirituality: In one survey of adult smokers, 88% reported a history of spiritual practice or belief, and of those more than three-quarters were of the opinion that using spiritual resources may help them quit smoking.
A review of mindfulness training as a treatment for addiction showed reduction in craving and smoking following training.
Physical activities help in the maintenance of smoking cessation even if there is no conclusive evidence of the most appropriate exercise intensity.
Various methods exist which allow a smoker to see the impact of their tobacco use, and the immediate effects of quitting. Using biochemical feedback methods can allow tobacco-users to be identified and assessed, and the use of monitoring throughout an effort to quit can increase motivation to quit. A recent Cochrane Review found "little evidence about the effects of most types of biomedical tests for risk assessment on smoking cessation,".[needs update]
Breath carbon monoxide (CO) monitoring: Because carbon monoxide is a significant component of cigarette smoke, a breath carbon monoxide monitor can be used to detect recent cigarette use. Carbon monoxide concentration in breath has been shown to be directly correlated with the CO concentration in blood, known as percent carboxyhemoglobin. The value of demonstrating blood CO concentration to a smoker through a non-invasive breath sample is that it links the smoking habit with the physiological harm associated with smoking. Within hours of quitting, CO concentrations show a noticeable decrease, and this can be encouraging for someone working to quit. Breath CO monitoring has been utilized in smoking cessation as a tool to provide patients with biomarker feedback, similar to the way in which other diagnostic tools such as the stethoscope, the blood pressure cuff, and the cholesterol test have been used by treatment professionals in medicine.
Cotinine: A metabolite of nicotine, cotinine is present in smokers. Like carbon monoxide, a cotinine test can serve as a reliable biomarker to determine smoking status. Cotinine levels can be tested through urine, saliva, blood, or hair samples, with one of the main concerns of cotinine testing being the invasiveness of typical sampling methods.
While both measures offer high sensitivity and specificity, they differ in usage method and cost. As an example, breath CO monitoring is non-invasive, while cotinine testing relies on a bodily fluid. These two methods can be used either alone or together, for example, in a situation where abstinence verification needs additional confirmation.
Competitions and incentives
Financial or material incentives to entice people to quit smoking improves smoking cessation while the incentive is in place. Competitions that require participants to deposit their own money, "betting" that they will succeed in their efforts to quit smoking, appear to be an effective incentive. However, in head to head comparisons with other incentive models such as giving participants NRT or placing them in a more typical rewards program, it is more difficult to recruit participants for this type of contest. There is evidence that incentive programs may be effective for pregnant mothers who smoke.
A different 2008 Cochrane review found that one type of competition, "Quit and Win," did increase quit rates among participants.
Interventions delivered via healthcare providers and healthcare systems have been shown to improve smoking cessation among people who visit those services.
A clinic screening system (e.g., computer prompts) to identify whether or not a person smokes doubled abstinence rates, from 3.1% to 6.4%.:78–79 Similarly, the Task Force on Community Preventive Services determined that provider reminders alone or with provider education are effective in promoting smoking cessation.:33–38
A 2008 Guideline meta-analysis estimated that physician advice to quit smoking led to a quit rate of 10.2%, as opposed to a quit rate of 7.9% among patients who did not receive physician advice to quit smoking.:82–83 A Cochrane review found that even brief advice from physicians had "a small effect on cessation rates,". However, one study from Ireland involving vignettes found that physicians' probability of giving smoking cessation advice declines with the patient's age, and another study from the U.S. found that only 81% of smokers age 50 or greater received advice on quitting from their physicians in the preceding year.
For one-to-one or person-to-person counselling sessions, the duration of each session, the total amount of contact time, and the number of sessions all correlated with the effectiveness of smoking cessation. For example, "Higher intensity" interventions (>10 minutes) produced a quit rate of 22.1% as opposed to 10.9% for "no contact" over 300 minutes of contact time produced a quit rate of 25.5% as opposed to 11.0% for "no minutes" and more than 8 sessions produced a quit rate of 24.7% as opposed to 12.4% for 0–1 sessions.:83–86
Both physicians and non-physicians increased abstinence rates compared with self-help or no clinicians.:87–88 For example, a Cochrane review of 35 studies found that nursing interventions increased the likelihood of quitting.[needs update] Another review found some positive effects when trained community pharmacists support the customers in their smoking cessation trials.
Dental professionals also provide a key component in increasing tobacco abstinence rates in the community through counseling patients on the effects of tobacco on oral health in conjunction with an oral exam.
According to the 2008 Guideline, based on two studies the training of clinicians in smoking cessation methods may increase abstinence rates;:130 however, a Cochrane review found and measured that such training decreased smoking in patients.
Reducing or eliminating the costs of cessation therapies for smokers increased quit rates in three meta-analyses.:139–140:38–40
In one systematic review and meta-analysis, multi-component interventions increased quit rates in primary care settings. "Multi-component" interventions were defined as those that combined two or more of the following strategies known as the "5 A's"::38–43
Ask — Systematically identify all tobacco users at every visit
Advise — Strongly urge all tobacco users to quit
Breath CO monitor displaying carbon monoxide concentration of an exhaled breath sample (in ppm) with its corresponding percent concentration of carboxyhemoglobin.
Assess — Determine willingness to make a quit attempt
Assist — Aid the patient in quitting (provide counselling-style support and medication)
Arrange — Ensure follow-up contact
Substitutes for cigarettes
Main articles: Nicotine replacement therapy and Electronic cigarette § Smoking cessation
Nicotine replacement therapy (NRT) is the general term for using products that contain nicotine but not tobacco to aid cessation of smoking. These include nicotine lozenges that are sucked, nicotine gum and inhalers, nicotine patches, as well as electronic cigarettes.
Electronic cigarette: There is limited supporting evidence in helping people quit smoking. The available evidence for their effectiveness in abstaining from smoking is inconclusive. A 2018 review stated for people who are only willing to vape to quit smoking, they recommended that these people be told that little is known regarding the long-term harms related to vaping. A 2016 UK Royal College of Physicians report supports the use of e-cigarettes as a smoking cessation tool. A 2015 Public Health England report stated that "Smokers who have tried other methods of quitting without success could be encouraged to try e-cigarettes (EC) to stop smoking and stop smoking services should support smokers using EC to quit by offering them behavioural support."
Acupuncture: Acupuncture has been explored as an adjunct treatment method for smoking cessation. A 2014 Cochrane review was unable to make conclusions regarding acupuncture as the evidence is poor. A 2008 guideline found no difference between acupuncture and placebo, found no scientific studies supporting laser therapy based on acupuncture principles but without the needles.:99
Chewing cinnamon sticks or gum has been recommended when trying to quit the use of tobacco.
Hypnosis: Hypnosis often involves the hypnotherapist suggesting to the patient the unpleasant outcomes of smoking. Clinical trials studying hypnosis and hypnotherapy as a method for smoking cessation have been inconclusive;:100 however, a randomized trial published in 2008 found that hypnosis and nicotine patches "compares favorably" with standard behavioral counseling and nicotine patches in 12-month quit rates.
Herbs: Many herbs have been studied as a method for smoking cessation, including lobelia and St John's wort,. The results are inconclusive, but St. Johns Wort shows few adverse events. Lobelia has been used to treat respiratory diseases like asthma and bronchitis, and has been used for smoking cessation because of chemical similarities to tobacco; lobelia is now listed in the FDA's Poisonous Plant Database. Lobelia can still be found in many products sold for smoking cessation and should be used with caution.
Smokeless tobacco: There is little smoking in Sweden, which is reflected in the very low cancer rates for Swedish men. Use of snus (a form of steam-pasteurised, rather than heat-pasteurised, air-cured smokeless tobacco) is an observed cessation method for Swedish men and even recommended by some Swedish doctors. However, the report by the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) concludes "STP (smokeless tobacco products) are addictive and their use is hazardous to health. Evidence on the effectiveness of STP as a smoking cessation aid is insufficient,". A recent national study on the use of alternative tobacco products, including snus, did not show that these products promote cessation.
Aversion therapy: It is a method of treatment works by pairing the pleasurable stimulus of smoking with other unpleasent stimului. A cochrane reviewe reported that there is insufficient evidence of its efficacy.
Nicotine vaccines: they are like NicVAX and TA-NIC. Nicotine vaccines work by reducing the amount of nicotine reaching the brain, however, this method of therapy needs more investigations to establish its role and determine its side effects.
Although smoking prevalence has declined in recent years leading up to 2016, certain subpopulations continue to smoke at disproportionately high rates and show resistance to cessation treatments.
Children and adolescents
Methods used with children and adolescents include:
Motivational enhancement [needs update]
Psychological support 
Youth anti-tobacco activities, such as sport involvement
School-based curricula, such as life-skills training
School-based nurse counseling sessions
Access reduction to tobacco
Cochrane reviews, mainly of studies combining motivational enhancement and psychological support, concluded that "complex approaches" for smoking cessation among young people show promise. The 2008 US Guideline recommends counselling-style support for adolescent smokers on the basis of a meta-analysis of seven studies.:159–161 Neither the Cochrane review nor the 2008 Guideline recommends medications for adolescents who smoke.
Smoking during pregnancy can cause adverse health effects in both the woman and the fetus. The 2008 US Guideline determined that "person-to-person psychosocial interventions" (typically including "intensive counseling") increased abstinence rates in pregnant women who smoke to 13.3%, compared with 7.6% in usual care.:165–167 Mothers who smoke during pregnancy have a greater tendency towards premature births. Their babies are often underdeveloped, have smaller organs, and weigh much less than the normal baby. In addition, these babies have weaker immune systems, making them more susceptible to many diseases such as middle ear inflammations and asthmatic bronchitis, which can bring significant morbidity. There is also an increased chance that the child will be a smoker in adulthood. A systematic review showed that psychosocial interventions help women to stop smoking in late pregnancy and can reduce the incidence of low birthweight infants.
It is a myth that a female smoker can cause harm to a fetus by quitting immediately upon discovering she is pregnant. This idea is not based on any medical study or fact.
Main article: Schizophrenia and smoking
Studies across 20 countries show a strong association between patients with schizophrenia and smoking. People with schizophrenia are much more likely to smoke than those without the disease. For example, in the United States, 80% or more of people with schizophrenia smoke, compared to 20% of the general population in 2006.
A 2008 Cochrane review of smoking cessation activities in work-places concluded that "interventions directed towards individual smokers increase the likelihood of quitting smoking,". A 2010 systematic review determined that worksite incentives and competitions needed to be combined with additional interventions to produce significant increases in smoking cessation rates.
Percent increase of success for six months over unaided attempts for each type of quitting (chart from West & Shiffman based on Cochrane review data:59
Smokers who are hospitalised may be particularly motivated to quit.:149–150 A 2012 Cochrane review found that interventions beginning during a hospital stay and continuing for one month or more after discharge were effective in producing abstinence.
Patients undergoing elective surgery may get benefits of preoperative smoking cessation interventions, when starting 4–8 weeks before surgery with weekly counselling intervention for behavioral support and use of nicotine replacement therapy. It is found to reduce the complications and the number of postoperative morbidity.
People who have mood disorders or attention deficit hyperactivity disorders have a greater chance to begin smoking and lower chance to quit smoking.
Homeless and poverty
Homelessness doubles the likelihood of an individual currently being a smoker. This is independent of other socioeconomic factors and behavioral health conditions. Homeless individuals have the same rates of the desire to quit smoking but are less likely than the general population to be successful in their attempt to quit.
In the United States, 60-80% of homeless adults are current smokers. This is a considerably higher rate than that of the general adult population of 19%. Many current smokers who are homeless report smoking as a means of coping with "all the pressure of being homeless." The perception that homeless people smoking is "socially acceptable" can also reinforce these trends.
Americans under the poverty line have higher rates of smoking and lower rates of quitting than those over the poverty line. It has been shown that while the homeless population as a whole is concerned about short-term effects of smoking such as shortness of breath of recurrent bronchitis, that are not as concerned with long-term consequences. The homeless population has unique barriers to quit smoking such as unstructured days, the stress of finding a job, and immediate survival needs that supersede the desire to quit smoking.
These unique barriers can be combated thusly: pharmacotherapy and behavioral counseling for high levels of nicotine dependence, emphasis of immediate financial benefits to those who concern themselves with the short-term over the long-term, partnering with shelters to reduce the social acceptability of smoking in this population, increased taxing not just on cigarettes but also on alternative tobacco products, to further make the addiction more difficult to fund.
People living with HIV/AIDS
Smoking is very common among people living with HIV/AIDS(PLWHA) and it impacts morbidity and mortality substantialy. Combined smoking cessation interventions provide good long-term control.
Comparison of success rates
Individuals who sustained damage to the insula were able to more easily abstain from smoking.
Comparison of success rates across interventions can be difficult because of different definitions of "success" across studies. Robert West and Saul Shiffman, authorities in this field recognized by government health departments in a number of countries,:73,76,80 have concluded that, used together, "behavioral support" and "medication" can quadruple the chances that a quit attempt will be successful.
A 2008 systematic review in the European Journal of Cancer Prevention found that group behavioural therapy was the most effective intervention strategy for smoking cessation, followed by bupropion, intensive physician advice, nicotine replacement therapy, individual counselling, telephone counselling, nursing interventions, and tailored self-help interventions; the study did not discuss varenicline.
Factors affecting success
Quitting can be harder for individuals with dark pigmented skin compared to individuals with pale skin since nicotine has an affinity for melanin-containing tissues. Studies suggest this can cause the phenomenon of increased nicotine dependence and lower smoking cessation rate in darker pigmented individuals.
There is an important social component to smoking. A 2008 study of a densely interconnected network of over 12,000 individuals found that smoking cessation by any given individual reduced the chances of others around them lighting up by the following amounts: a spouse by 67%, a sibling by 25%, a friend by 36%, and a coworker by 34%. Nevertheless, a Cochrane review determined that interventions to increase social support for a smoker's cessation attempt did not increase long-term quit rates.[needs update]
Smokers who are trying to quit are faced with social influences that may persuade them to conform and continue smoking. Cravings are easier to detain when one's environment does not provoke the habit. If a person who stopped smoking has close relationships with active smokers, he or she is often put into situations that make the urge to conform more tempting. However, in a small group with at least one other not smoking, the likelihood of conformity decreases.
The social influence to smoke cigarettes has been proven to rely on simple variables. One researched variable depends on whether the influence is from a friend or non-friend. The research shows that individuals are 77% more likely to conform to non-friends, while close friendships decrease conformity. Therefore, if an acquaintance offers a cigarette as a polite gesture, the person who has stopped smoking will be more likely to break his commitment than if a friend had offered. Recent research from the International Tobacco Control (ITC) Four Country Survey of over 6,000 smokers found that smokers with fewer smoking friends were more likely to intend to quit and to succeed in their quit attempt.
Expectations and attitude are significant factors. A self-perpetuating cycle occurs when a person feels bad for smoking yet smokes to alleviate feeling bad. Breaking that cycle can be a key in changing the sabotaging attitude.
Smokers with major depressive disorder may be less successful at quitting smoking than non-depressed smokers.:81
Relapse (resuming smoking after quitting) has been related to psychological issues such as low self-efficacy, or non-optimal coping responses; however, psychological approaches to prevent relapse have not been proven to be successful. In contrast, varenicline is suggested to have some effects and nicotine replacement therapy may help the unassissted abstainers.
Duration of nicotine withdrawal symptoms
Craving for tobacco
3 to 8 weeks
1 to 2 weeks
1 to 2 weeks
1 to 2 weeks
1 to 2 weeks
2 to 4 weeks
2 to 4 weeks
Cough or nasal drip
Lack of concentration
Up to several weeks
In a 2007 review of the effects of abstinence from tobacco, Hughes concluded that "anger, anxiety, depression, difficulty concentrating, impatience, insomnia, and restlessness are valid withdrawal symptoms that peak within the first week and last 2–4 weeks." In contrast, "constipation, cough, dizziness, increased dreaming, and mouth ulcers" may or may not be symptoms of withdrawal, while drowsiness, fatigue, and certain physical symptoms ("dry mouth, flu symptoms, headaches, heart racing, skin rash, sweating, tremor") were not symptoms of withdrawal.
Giving up smoking is associated with an average weight gain of 4–5 kilograms (8.8–11.0 lb) after 12 months, most of which occurs within the first three months of quitting.
The possible causes of the weight gain include:
Smoking over-expresses the gene AZGP1 which stimulates lipolysis, so smoking cessation may decrease lipolysis.
Smoking suppresses appetite, which may be caused by nicotine's effect on central autonomic neurons (e.g., via regulation of melanin concentrating hormone neurons in the hypothalamus).
Heavy smokers are reported to burn 200 calories per day more than non-smokers eating the same diet. Possible reasons for this phenomenon include nicotine's ability to increase energy metabolism or nicotine's effect on peripheral neurons.
The 2008 Guideline suggests that sustained-release bupropion, nicotine gum, and nicotine lozenge be used "to delay weight gain after quitting.":173–176 A 2012 Cochrane review concluded that there is not sufficient evidence to recommend a particular program for preventing weight gain.
Like other physically addictive drugs, nicotine addiction causes a down-regulation of the production of dopamine and other stimulatory neurotransmitters as the brain attempts to compensate for the artificial stimulation caused by smoking. Therefore, when people stop smoking, depressive symptoms such as suicidal tendencies or actual depression may result, although a recent international study comparing smokers who had stopped for 3 months with continuing smokers found that stopping smoking did not appear to increase anxiety or depression. This side effect of smoking cessation may be particularly common in women, as depression is more common among women than among men.
A recent study by The British Journal of Psychiatry has found that smokers who successfully quit feel less anxious afterward with the effect being greater among those who had mood and anxiety disorders than those that smoked for pleasure.
Many of tobacco's detrimental health effects can be reduced or largely removed through smoking cessation. The health benefits over time of stopping smoking include:
Within 20 minutes after quitting, blood pressure and heart rate decrease
Within 12 hours, carbon monoxide levels in the blood decrease to normal
Within 48 hours, nerve endings and sense of smell and taste both start recovering
Within 3 months, circulation and lung function improve
Within 9 months, there are decreases in cough and shortness of breath
Within 1 year, the risk of coronary heart disease is cut in half
Within 5 years, the risk of stroke falls to the same as a non-smoker, and the risks of many cancers (mouth, throat, esophagus, bladder, cervix) decrease significantly
Within 10 years, the risk of dying from lung cancer is cut in half, and the risks of larynx and pancreas cancers decrease
Within 15 years, the risk of coronary heart disease drops to the level of a non-smoker; lowered risk for developing COPD (chronic obstructive pulmonary disease)
The British Doctors Study showed that those who stopped smoking before they reached 30 years of age lived almost as long as those who never smoked. Stopping in one's sixties can still add three years of healthy life. A randomized trial from the U.S. and Canada showed that a smoking cessation program lasting 10 weeks decreased mortality from all causes over 14 years later. A recent article on mortality in a cohort of 8,645 smokers who were followed-up after 43 years determined that “current smoking and lifetime persistent smoking were associated with an increased risk of all-cause, CVD [cardiovascular disease], COPD [chronic obstructive pulmonary disease], and any cancer, and lung cancer mortality.
Another published study, "Smoking Cessation Reduces Postoperative Complications: A Systematic Review and Meta-analysis," examined six randomized trials and 15 observational studies to look at the effects of preoperative smoking cessation on postoperative complications. The findings were: 1) taken together, the studies demonstrated decreased the likelihood of postoperative complications in patients who ceased smoking prior to surgery; 2) overall, each week of cessation prior to surgery increased the magnitude of the effect by 19%. A significant positive effect was noted in trials where smoking cessation occurred at least four weeks prior to surgery; 3) For the six randomized trials, they demonstrated on average a relative risk reduction of 41% for postoperative complications.
Smokers as a percentage of the population for the United States, the Netherlands, Norway, Japan, and Finland.
Cost-effectiveness analyses of smoking cessation activities have shown that they increase quality-adjusted life years (QALYs) at costs comparable with other types of interventions to treat and prevent disease.:134–137 Studies of the cost-effectiveness of smoking cessation include:
In a 1997 U.S. analysis, the estimated cost per QALY varied by the type of cessation approach, ranging from group intensive counselling without nicotine replacement at $1108 per QALY to minimal counselling with nicotine gum at $4542 per QALY.
A study from Erasmus University Rotterdam limited to people with chronic obstructive pulmonary disease found that the cost-effectiveness of minimal counselling, intensive counselling, and drug therapy were €16,900, €8,200, and €2,400 per QALY gained respectively.
Among National Health Service smoking cessation clients in Glasgow, pharmacy one-to-one counselling cost £2,600 per QALY gained and group support cost £4,800 per QALY gained.
The frequency of smoking cessation among smokers varies across countries. Smoking cessation increased in Spain between 1965 and 2000, in Scotland between 1998 and 2007, and in Italy after 2000. In contrast, in the U.S. the cessation rate was "stable (or varied little)" between 1998 and 2008, and in China smoking cessation rates declined between 1998 and 2003.
Nevertheless, in a growing number of countries there are now more ex-smokers than smokers  For example, in the U.S. as of 2010, there were 47 million ex-smokers and 46 million smokers. In 2014, the Centers for Disease Control and Prevention reports that the number of adult smokers, 18 years and older, in the U.S. has fallen to 40 million current smokers.
American Legacy Foundation
Carbon monoxide breath monitor
Massachusetts Tobacco Cessation and Prevention Program
Nicotine replacement therapy
Smoking cessation programs in Canada
Tobacco and health
Tobacco cessation clinic
U.S. government and smoking cessation
Youth Tobacco Cessation Collaborative
World No Tobacco Day
^ ab"Guide to quitting smoking". American Cancer Society. 2016. Retrieved 2016-07-22.
^ abMooney ME, Johnson EO, Breslau N, Bierut LJ, Hatsukami DK (2011). "Cigarette smoking reduction and changes in nicotine dependence". Nicotine and Tobacco Research. 13 (6): 426–430. doi:10.1093/ntr/ntr019. PMC 3103717. PMID 21367813.
^Sudeep C B (2017). "TOBACCO CESSATION COUNSELING – THE ROLES AND RESPONSIBILITIES OF A DENTIST". International Journal of Advanced Research. 5 (3): 326–331. doi:10.21474/IJAR01/3518.
^Centers for Disease Control Prevention (CDC) (Nov 11, 2011). "Quitting smoking among adults--United States, 2001-2010". MMWR. Morbidity and Mortality Weekly Report. 60 (44): 1513–1519. ISSN 1545-861X. PMID 22071589. Retrieved 2015-05-09.
^Orisasami, Isimat Temitayo; Ojo, Omorogieva (2016). "Evaluating the effectiveness of smoking cessation in the management of COPD". British Journal of Nursing. 25 (14): 786–790. doi:10.12968/bjon.2016.25.14.786. PMID 27467642.
^World Health Organization. WHO Report on the global tobacco epidemic. 2015. http://www.who.int/tobacco/global_report/2015/en/
^Rigotti, Nancy A. (Oct 17, 2012). "Strategies to help a smoker who is struggling to quit". JAMA. 308 (15): 1573–1580. doi:10.1001/jama.2012.13043. ISSN 1538-3598. PMC 4562427. PMID 23073954.
^Stead, Lindsay F.; Lancaster, Tim (2016). "Combined pharmacotherapy and behavioural interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 3: CD008286. doi:10.1002/14651858.CD008286.pub3. PMID 27009521.
^ abcdefRosen, Laura J.; Galili, Tal; Kott, Jeffrey; Goodman, Mark; Freedman, Laurence S. (2018). "Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials". Addiction. 113 (5): 805–816. doi:10.1111/add.14134. ISSN 0965-2140. PMC 5947828. PMID 29377409.
^Benowitz NL; Benowitz, Neal L. (2010). "Nicotine addiction". N Engl J Med. 362 (24): 2295–303. doi:10.1056/NEJMra0809890. PMC 2928221. PMID 20554984.
^ abcdefghijklmnopqrstuvwxyzFiore MC, et al. (2008). Clinical practice guideline: treating tobacco use and dependence: 2008 update(PDF). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Archived from the original (PDF) on 2016-03-27. Retrieved 2016-07-06.
^Fiore MC, et al. (1996). Smoking cessation. Clinical practice guideline no. 18. AHCPR publication no. 96-0692. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
^Fiore MC, et al. (2000). Clinical practice guideline: treating tobacco use and dependence(PDF). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Archived from the original (PDF) on 2011-01-07. Retrieved 2011-02-16.
^ abChaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, Philipneri A, Schwartz R (2016). "Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers". BMJ Open. 6 (6): e011045. doi:10.1136/bmjopen-2016-011045. PMC 4908897. PMID 27288378.
^Caraballo, Ralph S.; Shafer, Paul R.; Patel, Deesha; Davis, Kevin C.; McAfee, Timothy A. (13 April 2017). "Quit Methods Used by US Adult Cigarette Smokers, 2014–2016". Preventing Chronic Disease. 14: E32. doi:10.5888/pcd14.160600. PMC 5392446. PMID 28409740.
^Hughes JR, Keely J, Naud S (2004). "Shape of the relapse curve and long-term abstinence among untreated smokers". Addiction. 99 (1): 29–38. doi:10.1111/j.1360-0443.2004.00540.x. PMID 14678060.
^ abEdwards SA, Bondy SJ, Callaghan RC, Mann RE (2014). "Prevalence of unassisted quit attempts in population-based studies: a systematic review of the literature". Addictive Behaviors. 39 (3): 512–9. doi:10.1016/j.addbeh.2013.10.036. PMID 24333037.
^ abcLee CW, Kahende J (2007). "Factors associated with successful smoking cessation in the United States, 2000". Am J Public Health. 97 (8): 1503–9. doi:10.2105/AJPH.2005.083527. PMC 1931453. PMID 17600268.
^Fiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, Surawicz TS, Davis RM (1990). "Methods used to quit smoking in the United States. Do cessation programs help?". JAMA. 263 (20): 2760–5. doi:10.1001/jama.1990.03440200064024. PMID 2271019.
^Doran CM, Valenti L, Robinson M, Britt H, Mattick RP (2006). "Smoking status of Australian general practice patients and their attempts to quit". Addict Behav. 31 (5): 758–66. doi:10.1016/j.addbeh.2005.05.054. PMID 16137834.
^ abChapman S, MacKenzie R (2010-02-09). "The global research neglect of unassisted smoking cessation: causes and consequences". PLoS Medicine. 7 (2): e1000216. doi:10.1371/journal.pmed.1000216. PMC 2817714. PMID 20161722.
^Hung WT, Dunlop SM, Perez D, Cotter T (2011). "Use and perceived helpfulness of smoking cessation methods: results from a population survey of recent quitters". BMC Public Health. 11: 592. doi:10.1186/1471-2458-11-592. PMC 3160379. PMID 21791111.
^"Guide to quitting smoking. What do I need to know about quitting" (PDF). American Cancer Society. 2014. Retrieved 2016- 7. Check date values in: |accessdate= (help)
^ abcHartmann-Boyce, J; Chepkin, SC; Ye, W; Bullen, C; Lancaster, T (31 May 2018). "Nicotine replacement therapy versus control for smoking cessation". The Cochrane Database of Systematic Reviews. 5: CD000146. doi:10.1002/14651858.CD000146.pub5. PMID 29852054.
^Hartmann‐Boyce, Jamie; Chepkin, Samantha C.; Ye, Weiyu; Bullen, Chris; Lancaster, Tim (2018). "Nicotine replacement therapy versus control for smoking cessation". Cochrane Database of Systematic Reviews. 5 (5): CD000146. doi:10.1002/14651858.CD000146.pub5. ISSN 1465-1858. PMC 6353172. PMID 29852054.
^Millstone K (2007-02-13). "Nixing the patch: Smokers quit cold turkey". Columbia.edu News Service. Retrieved 2011-02-21.
^Lancaster, T; Stead, LF (2000). "Mecamylamine (a nicotine antagonist) for smoking cessation". The Cochrane Database of Systematic Reviews (2): CD001009. doi:10.1002/14651858.CD001009. PMID 10796584.
^ abJohn R Hughes; et al. (2014). "Antidepressants for smoking cessation". Cochrane Database of Systematic Reviews. 1 (1): CD000031. doi:10.1002/14651858.CD000031.pub4. PMID 24402784.
^Pfizer (2015). "Product monograph Champix" (PDF). Archived from the original (PDF) on 2015-11-16. Retrieved 2016-07. Check date values in: |accessdate= (help)
^ abcdeCahill, Kate; Lindson-Hawley, Nicola; Thomas, Kyla H.; Fanshawe, Thomas R.; Lancaster, Tim (2016-05-09). "Nicotine receptor partial agonists for smoking cessation". The Cochrane Database of Systematic Reviews (5): CD006103. doi:10.1002/14651858.CD006103.pub7. hdl:1983/0cbd99fb-032e-4547-95cc-e314a8d042d7. ISSN 1469-493X. PMC 6464943. PMID 27158893.
^Singh S, Loke Y, Spangler J, Furberg C (July 4, 2011). "Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis". Canadian Medical Association Journal. 183 (12): 1359–66. doi:10.1503/cmaj.110218. PMC 3168618. PMID 21727225.
^Anthenelli, RM; Benowitz, NL; West, R; St Aubin, L; McRae, T; Lawrence, D; Ascher, J; Russ, C; Krishen, A; Evins, AE (18 June 2016). "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial". Lancet. 387 (10037): 2507–20. doi:10.1016/s0140-6736(16)30272-0. PMID 27116918.
^Hughes, JR; Stead, LF; Lancaster, T (2000). "Anxiolytics for smoking cessation". The Cochrane Database of Systematic Reviews (4): CD002849. doi:10.1002/14651858.CD002849. PMID 11034774.
^ abCahill, K; Ussher, MH (16 March 2011). "Cannabinoid type 1 receptor antagonists for smoking cessation". The Cochrane Database of Systematic Reviews (3): CD005353. doi:10.1002/14651858.CD005353.pub4. PMID 21412887.
^Phend C (2009-04-03). "Gradual cutback with nicotine replacement boosts quit rates". MedPage Today. Retrieved 2011-02-20.
^Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P (2009). "Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis". BMJ. 338: b1024. doi:10.1136/bmj.b1024. PMC 2664870. PMID 19342408.
^Lindson-Hawley N, Aveyard P, Hughes JR (2012). Lindson-Hawley N (ed.). "Reduction versus abrupt cessation in smokers who want to quit" (PDF). Cochrane Database of Systematic Reviews. 11 (11): CD008033. doi:10.1002/14651858.CD008033.pub3. PMID 23152252.
^"Making a Quit Plan". Centers for Disease Control and Prevention. Retrieved 19 October 2015.
^"Preparing for Quit Day". Mayo Clinic. Mayo Clinic. Retrieved 19 October 2015.
^Smit, Eline; Hoving, Ciska; Schelleman-Offermans, Karen; West, Robert; de Vries, Hein (September 2014). "Predictors of successful and unsuccessful quit attempts among smokers motivated to quit" (PDF). Addictive Behaviors. 39 (9): 1318–1324. doi:10.1016/j.addbeh.2014.04.017. PMID 24837754.
^de Vries, Hein; Eggers, Sander; Bolman, Catherine (April 2013). "The role of action planning and plan enactment for smoking cessation". BMC Public Health. 13: 393. doi:10.1186/1471-2458-13-393. PMC 3644281. PMID 23622256.
^Bolmana, Catherine; Matthijs Eggersb, Sander; van Oschb, Liesbeth; Te Poelc, Fam; Candeld, Math; de Vries, Hein (Oct 2015). "Is Action Planning Helpful for Smoking Cessation? Assessing the Effects of Action Planning in a Web-Based Computer-Tailored Intervention". Substance Use & Misuse. 50 (10): 1249–1260. doi:10.3109/10826084.2014.977397. PMID 26440754.
^Erbas, Bircan; Bui, Quang; Huggins, Richard; Harper, Todd; White, Victoria (Feb 2006). "Investigating the relation between placement of Quit antismoking advertisements and number of telephone calls to Quitline: a semiparametric modelling approach". Journal of Epidemiology and Community Health. 60 (1): 180–182. doi:10.1136/jech.2005.038109. PMC 2566152. PMID 16415271.
^Secker-Walker RH, Gnich W, Platt S, Lancaster T (2002). Stead LF (ed.). "Community interventions for reducing smoking among adults". Cochrane Database Syst Rev (3): CD001745. doi:10.1002/14651858.CD001745. PMC 6464950. PMID 12137631.
^ abLemmens V, Oenema A, Knut IK, Brug J (2008). "Effectiveness of smoking cessation interventions among adults: a systematic review of reviews" (PDF). Eur J Cancer Prev. 17 (6): 535–44. doi:10.1097/CEJ.0b013e3282f75e48. PMID 18941375. Archived from the original (PDF) on 2011-07-06.
^"State-Mandated Tobacco Ban, Integration of Cessation Services, and Other Policies Reduce Smoking Among Patients and Staff at Substance Abuse Treatment Centers". Agency for Healthcare Research and Quality. 2013-02-27. Retrieved 2013-05-13.
^Centers for Disease Control and Prevention (CDC) (May 2007). "State-specific prevalence of smoke-free home rules--United States, 1992-2003". MMWR Morb. Mortal. Wkly. Rep. 56 (20): 501–4. PMID 17522588.
^King, BA; Dube, SR; Homa, DM (16 May 2013). "Smoke-free rules and secondhand smoke exposure in homes and vehicles among US adults, 2009-2010". Preventing Chronic Disease. 10: E79. doi:10.5888/pcd10.120218. PMC 3666976. PMID 23680508.
^King, BA; Babb, SD; Tynan, MA; Gerzoff, RB (July 2013). "National and state estimates of secondhand smoke infiltration among U.S. multiunit housing residents". Nicotine & Tobacco Research. 15 (7): 1316–21. doi:10.1093/ntr/nts254. PMC 4571449. PMID 23248030.
^ abcdeHopkins DP, Briss PA, Ricard CJ, Husten CG, Carande-Kulis VG, Fielding JE, Alao MO, McKenna JW, Sharp DJ, Harris JR, Woollery TA, Harris KW; Task Force on Community Preventive Services (2001). "Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke" (PDF). Am J Prev Med. 20 (2 Suppl): 16–66. doi:10.1016/S0749-3797(00)00297-X. PMID 11173215.CS1 maint: Multiple names: authors list (link)
^Bala, MM; Strzeszynski, L; Topor-Madry, R (21 November 2017). "Mass media interventions for smoking cessation in adults". The Cochrane Database of Systematic Reviews. 11: CD004704. doi:10.1002/14651858.CD004704.pub4. PMID 29159862.
^Frazer, Kate; McHugh, Jack; Callinan, Joanne E.; Kelleher, Cecily (2016-05-27). "Impact of institutional smoking bans on reducing harms and secondhand smoke exposure". The Cochrane Database of Systematic Reviews (5): CD011856. doi:10.1002/14651858.CD011856.pub2. ISSN 1469-493X. PMID 27230795.
^Zhu SH, Anderson CM, Tedeschi GJ, Rosbrook B, Johnson CE, Byrd M, Gutiérrez-Terrell E (2002). "Evidence of real-world effectiveness of a telephone quitline for smokers" (PDF). N Engl J Med. 347 (14): 1087–93. doi:10.1056/NEJMsa020660. PMID 12362011.CS1 maint: Multiple names: authors list (link)
^Helgason AR, Tomson T, Lund KE, Galanti R, Ahnve S, Gilljam H (2004). "Factors related to abstinence in a telephone helpline for smoking cessation". Eur J Public Health. 14 (3): 306–10. doi:10.1093/eurpub/14.3.306. PMID 15369039.CS1 maint: Multiple names: authors list (link)
^Stead, LF; Hartmann-Boyce, J; Perera, R; Lancaster, T (12 August 2013). "Telephone counselling for smoking cessation". The Cochrane Database of Systematic Reviews (8): CD002850. doi:10.1002/14651858.CD002850.pub3. PMID 23934971.
^Lancaster, T; Stead, LF (31 March 2017). "Individual behavioural counselling for smoking cessation". The Cochrane Database of Systematic Reviews. 3: CD001292. doi:10.1002/14651858.CD001292.pub3. PMC 6464359. PMID 28361496.
^Stead, LF; Koilpillai, P; Lancaster, T (12 October 2015). "Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation". The Cochrane Database of Systematic Reviews (10): CD009670. doi:10.1002/14651858.CD009670.pub3. PMID 26457723.
^"Quitza - The Ex Smokers Social Network". Quitza. Retrieved 2016-07-01.
^Baskerville, Neill Bruce; Azagba, Sunday; Norman, Cameron; McKeown, Kyle; Brown, K. Stephen (2015-06-04). "Effect of a Digital Social Media Campaign on Young Adult Smoking Cessation". Nicotine & Tobacco Research. 18 (3): 351–60. doi:10.1093/ntr/ntv119. ISSN 1462-2203. PMID 26045252.
^Stead, LF; Carroll, AJ; Lancaster, T (31 March 2017). "Group behaviour therapy programmes for smoking cessation". The Cochrane Database of Systematic Reviews. 3: CD001007. doi:10.1002/14651858.CD001007.pub3. PMC 6464070. PMID 28361497.
^Lindson-Hawley, N; Thompson, TP; Begh, R (2 March 2015). "Motivational interviewing for smoking cessation". The Cochrane Database of Systematic Reviews (3): CD006936. doi:10.1002/14651858.CD006936.pub3. PMID 25726920.
^Hettema, JE; Hendricks, PS (December 2010). "Motivational interviewing for smoking cessation: a meta-analytic review". Journal of Consulting and Clinical Psychology. 78 (6): 868–84. doi:10.1037/a0021498. PMID 21114344.
^Heckman, CJ; Egleston, BL; Hofmann, MT (October 2010). "Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis". Tobacco Control. 19 (5): 410–6. doi:10.1136/tc.2009.033175. PMC 2947553. PMID 20675688.
^Perkins KA, Conklin CA, Levine MD (2008). Cognitive-behavioral therapy for smoking cessation: a practical guidebook to the most effective treatment. New York: Routledge. ISBN 978-0-415-95463-1.
^Ruiz, F. J. (2010). "A review of Acceptance and Commitment Therapy (ACT) empirical evidence: Correlational, experimental psychopathology, component and outcome studies". International Journal of Psychology and Psychological Therapy. 10 (1): 125–62.
^"About Freedom From Smoking". American Lung Association.
^Prochaska JO, Velicer WF, DiClemente CC, Fava J (1988). "Measuring processes of change: applications to the cessation of smoking". J Consult Clin Psychol. 56 (4): 520–8. doi:10.1037/0022-006X.56.4.520. PMID 3198809.
^DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS (1991). "The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change" (PDF). J Consult Clin Psychol. 59 (2): 295–304. doi:10.1037/0022-006X.59.2.295. PMID 2030191. Archived from the original (PDF) on 2011-06-06. Retrieved 2011-02-15.
^Prochaska JO, DiClemente CC, Velicer WF, Rossi JS (1993). "Standardized, individualized, interactive, and personalized self-help programs for smoking cessation" (PDF). Health Psychol. 12 (5): 399–405. doi:10.1037/0278-622.214.171.1249. PMID 8223364. Archived from the original (PDF) on 2011-06-06. Retrieved 2011-02-15.
^Cahill K, Lancaster T, Green N (2010). Cahill K (ed.). "Stage-based interventions for smoking cessation". Cochrane Database Syst Rev (11): CD004492. doi:10.1002/14651858.CD004492.pub4. PMID 21069681.
^Livingstone-Banks, J; Ordóñez-Mena, JM; Hartmann-Boyce, J (9 January 2019). "Print-based self-help interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 1: CD001118. doi:10.1002/14651858.CD001118.pub4. PMID 30623970.
^"Nicotine Anonymous offers help for those who desire to live free from nicotine". nicotine-anonymous.org.
^Glasser, I (February 2010). "Nicotine anonymous may benefit nicotine-dependent individuals". American Journal of Public Health. 100 (2): 196, author reply 196–7. doi:10.2105/ajph.2009.181545. PMC 2804638. PMID 20019295.
^U.S. Department of Health and Human Services. "MySmokeFree: Your personalized quit experience". Smokefree.gov.
^"Slideshow: 13 Best Quit-Smoking Tips Ever". WebMD.
^Hendrick, B. [. http://www.webmd.com/smoking-cessation/news/20090526/computer-is-an-ally-in-quit-smoking-fight "Computer is an ally in quit-smoking fight"] Check |url= value (help). WebMD.
^Myung SK, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM (2009). "Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials". Arch Intern Med. 169 (10): 929–37. doi:10.1001/archinternmed.2009.109. PMID 19468084.
^Civljak, M; Stead, LF; Hartmann-Boyce, J; Sheikh, A; Car, J (10 July 2013). "Internet-based interventions for smoking cessation". The Cochrane Database of Systematic Reviews (7): CD007078. doi:10.1002/14651858.CD007078.pub4. PMID 23839868.
^Hutton HE, Wilson LM, Apelberg BJ, Avila Tang E, Odelola O, Bass EB, Chander G (Feb 2011). "A systematic review of randomized controlled trials: web-based interventions for smoking cessation among adolescents, college students, and adults". Nicotine Tob Res. 13 (4): 227–38. doi:10.1093/ntr/ntq252. PMID 21350042.
^Whittaker, R; McRobbie, H; Bullen, C; Rodgers, A; Gu, Y (10 April 2016). "Mobile phone-based interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 4: CD006611. doi:10.1002/14651858.CD006611.pub4. PMID 27060875.
^Free, C; Knight, R; Robertson, S; Whittaker, R; Edwards, P; Zhou, W; Rodgers, A; Cairns, J; Kenward, MG; Roberts, I (2 July 2011). "Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial". Lancet. 378 (9785): 49–55. doi:10.1016/s0140-6736(11)60701-0. PMC 3143315. PMID 21722952.
^Free, C; Phillips, G; Watson, L; Galli, L; Felix, L; Edwards, P; Patel, V; Haines, A (2013). "The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis". PLOS Medicine. 10 (1): e1001363. doi:10.1371/journal.pmed.1001363. PMC 3566926. PMID 23458994.
^Brendryen H.; Kraft P. (2008). "Happy ending: a randomized controlled trial of a digital multi-media smoking cessation intervention". Addiction. 103 (3): 478–84. doi:10.1111/j.1360-0443.2007.02119.x. PMID 18269367.
^Brendryen H.; Drozd F.; Kraft P. (2008). "A digital smoking cessation program delivered through internet and cell phone without nicotine replacement (happy ending): randomized controlled trial". J Med Internet Res. 10 (5): 555. doi:10.2196/jmir.1005. PMC 2630841. PMID 19087949.
^Carr A (2004). The easy way to stop smoking. New York: Sterling. ISBN 978-1-4027-7163-7.
^Gonzales D, Redtomahawk D, Pizacani B, Bjornson WG, Spradley J, Allen E, Lees P (2007). "Support for spirituality in smoking cessation: results of pilot survey". Nicotine Tob Res. 9 (2): 299–303. doi:10.1080/14622200601078582. PMID 17365761.
^Tang, Yi-Yuan; Tang, Rongxiang; Posner, Michael I. (2016). "Mindfulness meditation improves emotion regulation and reduces drug abuse". Drug and Alcohol Dependence. 163: S13–S18. doi:10.1016/j.drugalcdep.2015.11.041. PMID 27306725.
^Ussher, MH; Taylor, AH; Faulkner, GE (29 August 2014). "Exercise interventions for smoking cessation". The Cochrane Database of Systematic Reviews (8): CD002295. doi:10.1002/14651858.CD002295.pub5. PMID 25170798.
^ abBittoun R (2008). "Carbon monoxide meter: The essential clinical tool- the 'stethoscope"-of smoking cessation". Journal of Smoking Cessation. 3 (2): 69–70. doi:10.1375/jsc.3.2.69.
^Jamrozik K, Vessey M, Fowler G, Nicholas W, Parker G, van Vunakis H (1984). "Controlled trial of three different anti-smoking interventions in general practice". British Medical Journal. 288 (6429): 1499–1503. doi:10.1136/bmj.288.6429.1499.
^Bize, R; Burnand, B; Mueller, Y; Rège-Walther, M; Camain, JY; Cornuz, J (12 December 2012). "Biomedical risk assessment as an aid for smoking cessation". The Cochrane Database of Systematic Reviews. 12: CD004705. doi:10.1002/14651858.CD004705.pub4. PMID 23235615.
^Irving, JM; Clark, EC; Crombie, IK; Smith, WC (January 1988). "Evaluation of a portable measure of expired-air carbon monoxide". Preventive Medicine. 17 (1): 109–15. doi:10.1016/0091-7435(88)90076-x. PMID 3362796.
^Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G (2009). "Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology". Therapeutic Drug Monitoring. 31 (1): 14–30. doi:10.1097/FTD.0b013e3181957a3b. PMC 3644554. PMID 19125149.
^McClure, JB (2001). "Are biomarkers a useful aid in smoking cessation? A review and analysis of the literature". Behavioral Medicine. 27 (1): 37–47. doi:10.1080/08964280109595770. PMID 11575171.
^ abcCahill, Kate; Hartmann-Boyce, Jamie; Perera, Rafael (2015-05-18). "Incentives for smoking cessation". The Cochrane Database of Systematic Reviews (5): CD004307. doi:10.1002/14651858.CD004307.pub5. ISSN 1469-493X. PMID 25983287.
^Halpern, S.D.; French, B.; Small, D.S.; Saulsgiver, K. (2015-05-13). "Randomized Trial of Four Financial-Incentive Programs for Smoking Cessation". New England Journal of Medicine. 372 (22): 2108–2117. doi:10.1056/NEJMoa1414293. ISSN 1533-4406. PMC 4471993. PMID 25970009.
^Cahill K, Perera R (2008). Cahill K (ed.). "Quit and Win contests for smoking cessation". Cochrane Database Syst Rev (4): CD004986. doi:10.1002/14651858.CD004986.pub3. PMID 18843674.
^Stead, LF; Buitrago, D; Preciado, N; Sanchez, G; Hartmann-Boyce, J; Lancaster, T (31 May 2013). "Physician advice for smoking cessation". The Cochrane Database of Systematic Reviews (5): CD000165. doi:10.1002/14651858.CD000165.pub4. PMID 23728631.
^Maguire CP, Ryan J, Kelly A, O'Neill D, Coakley D, Walsh JB (2000). "Do patient age and medical condition influence medical advice to stop smoking?". Age Ageing. 29 (3): 264–6. doi:10.1093/ageing/29.3.264. PMID 10855911.
^Ossip-Klein DJ, McIntosh S, Utman C, Burton K, Spada J, Guido J (2000). "Smokers ages 50+: who gets physician advice to quit?" (PDF). Prev Med. 31 (4): 364–9. doi:10.1006/pmed.2000.0721. PMID 11006061.[permanent dead link]
^Rice, VH; Hartmann-Boyce, J; Stead, LF (12 August 2013). "Nursing interventions for smoking cessation". The Cochrane Database of Systematic Reviews (8): CD001188. doi:10.1002/14651858.CD001188.pub4. PMID 23939719.
^Sinclair, HK; Bond, CM; Stead, LF (2004). "Community pharmacy personnel interventions for smoking cessation". The Cochrane Database of Systematic Reviews (1): CD003698. doi:10.1002/14651858.CD003698.pub2. PMID 14974031.
^Carr AB, Ebbert J. interventions for tobacco cessation in the dental setting. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD005084. doi:10.1002/14651858.CD005084.pub3
^Carson KV, Verbiest ME, Crone MR, et al. (2012). Carson KV (ed.). "Training health professionals in smoking cessation" (PDF). Cochrane Database Syst Rev. 5 (5): CD000214. doi:10.1002/14651858.CD000214.pub2. PMID 22592671.
^Reda AA, Kaper J, Fikrelter H, Severens JL, van Schayck CP (2009). Van Schayck CP (ed.). "Healthcare financing systems for increasing the use of tobacco dependence treatment". Cochrane Database Syst Rev (2): CD004305. doi:10.1002/14651858.CD004305.pub3. PMID 19370599.
^Papadakis S, McDonald P, Mullen KA, Reid R, Skulsky K, Pipe A (2010). "Strategies to increase the delivery of smoking cessation treatments in primary care settings: a systematic review and meta-analysis". Prev Med. 51 (3–4): 199–213. doi:10.1016/j.ypmed.2010.06.007. PMID 20600264.
^McRobbie, Hayden; Bullen, Chris; Hartmann-Boyce, Jamie; Hajek, Peter; McRobbie, Hayden (2014). "Electronic cigarettes for smoking cessation and reduction". The Cochrane Library. 12 (12): CD010216. doi:10.1002/14651858.CD010216.pub2. PMID 25515689.
^Camenga, Deepa R.; Tindle, Hilary A. (2018). "Weighing the Risks and Benefits of Electronic Cigarette Use in High-Risk Populations". Medical Clinics of North America. 102 (4): 765–779. doi:10.1016/j.mcna.2018.03.002. ISSN 0025-7125. PMID 29933828.
^Formanek, Perry; Salisbury-Afshar, Elizabeth; Afshar, Majid (2018). "Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking". American Journal of Kidney Diseases. 72 (2): 255–266. doi:10.1053/j.ajkd.2018.01.057. ISSN 0272-6386. PMC 6057817. PMID 29661542.
^Royal College of Physicians (25 June 2014). "RCP statement on e-cigarettes". RCP London.
^McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). UK: Public Health England. p. 6.
^He, Dong; Berg, John E.; Høstmark, Arne T. (March 1997). "Effects of acupuncture on smoking cessation or reduction for motivated smokers". Preventive Medicine. 26 (2): 208–214. doi:10.1006/pmed.1996.0125. PMID 9085389.
^White, AR; Rampes, H; Liu, JP; Stead, LF; Campbell, J (23 January 2014). "Acupuncture and related interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 1 (1): CD000009. doi:10.1002/14651858.CD000009.pub4. PMID 24459016.
^US National Library of Medicine. "Smoking - tips on how to quit: MedlinePlus Medical Encyclopedia". medlineplus.gov.
^"Hypnosis for Quitting Smoking". WebMD. Retrieved 19 May 2012.
^Barnes J, Dong CY, McRobbie H, Walker N, Mehta M, Stead LF (2010). Barnes J (ed.). "Hypnotherapy for smoking cessation". Cochrane Database Syst Rev (10): CD001008. doi:10.1002/14651858.CD001008.pub2. PMID 20927723.
^Johnson, D.L.; Karkut, R.T. (October 1994). "Performance by gender in a stop-smoking program combining hypnosis and aversion". Psychological Reports. 75 (2): 851–7. doi:10.2466/pr0.19126.96.36.1991. PMID 7862796.
^Law, Malcolm; Tang, Jin Ling (1995). "An analysis of the effectiveness of interventions intended to help people stop smoking". Arch Intern Med. 155 (18): 1933–1941. doi:10.1001/archinte.1995.00430180025004. PMID 7575046.
^Carmody TP, Duncan C, Simon JA, Solkowitz S, Huggins J, Lee S, Delucchi K (2008). "Hypnosis for smoking cessation: a randomized trial". Nicotine Tob Res. 10 (5): 811–8. doi:10.1080/14622200802023833. PMID 18569754.
^Mayo Clinic. "St. John's wort (Hypericum perforatum) Evidence - Mayo Clinic". Mayo Clinic.
^Sood, A; Ebbert, JO; Prasad, K; Croghan, IT; Bauer, B; Schroeder, DR (July 2010). "A randomized clinical trial of St. John's wort for smoking cessation". Journal of Alternative and Complementary Medicine. 16 (7): 761–7. doi:10.1089/acm.2009.0445. PMC 3110810. PMID 20590478.
^U.S. Food and Drug Administration. "FDA Poisonous Plant Database". www.accessdata.fda.gov.
^SCENIHR. Health Effects of Smokeless Tobacco Products (PDF) (Report). p. 103.
^Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). "Health effects of smokeless tobacco products" (PDF).
^Popova, L; Ling, PM (May 2013). "Alternative tobacco product use and smoking cessation: a national study". American Journal of Public Health. 103 (5): 923–30. doi:10.2105/ajph.2012.301070. PMC 3661190. PMID 23488521.
^Hajek, P; Stead, LF (2004). "Aversive smoking for smoking cessation". The Cochrane Database of Systematic Reviews (3): CD000546. doi:10.1002/14651858.CD000546.pub2. PMID 15266433.
^Hartmann-Boyce, J; Cahill, K; Hatsukami, D; Cornuz, J (15 August 2012). "Nicotine vaccines for smoking cessation". The Cochrane Database of Systematic Reviews (8): CD007072. doi:10.1002/14651858.CD007072.pub2. PMID 22895958.
^Besson, Morgane; Forget, Benoît (2016). "Cognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial Perspective". Frontiers in Psychiatry. 7: 160. doi:10.3389/fpsyt.2016.00160. ISSN 1664-0640. PMC 5030478. PMID 27708591. This article incorporates text by Morgane Besson and Benoît Forget available under the CC BY 4.0 license.
^ abcStanton, A; Grimshaw, G (23 August 2013). "Tobacco cessation interventions for young people". The Cochrane Database of Systematic Reviews (8): CD003289. doi:10.1002/14651858.CD003289.pub5. PMID 23975659.
^Phert, L. "Intensive Counseling of Students by School Nurses Does Not Have Larger Impact on Long-Term Smoking Rates Than Briefer Sessions | AHRQ Health Care Innovations Exchange". innovations.ahrq.gov. Retrieved 19 July 2016.
^Davis, KC; Farrelly, MC; Messeri, P; Duke, J (February 2009). "The impact of national smoking prevention campaigns on tobacco-related beliefs, intentions to smoke and smoking initiation: results from a longitudinal survey of youth in the United States". International Journal of Environmental Research and Public Health. 6 (2): 722–40. doi:10.3390/ijerph6020722. PMC 2672353. PMID 19440412.
^Allen, JA; Duke, JC; Davis, KC; Kim, AE; Nonnemaker, JM; Farrelly, MC (Nov–Dec 2015). "Using mass media campaigns to reduce youth tobacco use: a review". American Journal of Health Promotion : AJHP. 30 (2): e71–82. doi:10.4278/ajhp.130510-lit-237. PMID 25372236.
^Carson, KV; Brinn, MP; Labiszewski, NA; Esterman, AJ; Chang, AB; Smith, BJ (6 July 2011). "Community interventions for preventing smoking in young people" (PDF). The Cochrane Database of Systematic Reviews (7): CD001291. doi:10.1002/14651858.CD001291.pub2. PMID 21735383.
^Chamberlain, Catherine; O'Mara-Eves, Alison; Porter, Jessie; Coleman, Tim; Perlen, Susan M.; Thomas, James; McKenzie, Joanne E. (2017-02-14). "Psychosocial interventions for supporting women to stop smoking in pregnancy" (PDF). The Cochrane Database of Systematic Reviews. 2: CD001055. doi:10.1002/14651858.CD001055.pub5. ISSN 1469-493X. PMC 4022453. PMID 28196405.
^Bowen, M (25 February 2013). "Pregnancy and smoking". Netdoctor. Retrieved 19 July 2016.
^de Leon, Jose; Diaz, Francisco J. (July 2005). "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors". Schizophrenia Research. 76 (2–3): 135–157. doi:10.1016/j.schres.2005.02.010. PMID 15949648.
^Keltner, Norman L.; Grant, Joan S. (November 2006). "Smoke, Smoke, Smoke That Cigarette". Perspectives in Psychiatric Care. 42 (4): 256–261. doi:10.1111/j.1744-6163.2006.00085.x. PMID 17107571.
^Cahill, K; Lancaster, T (26 February 2014). "Workplace interventions for smoking cessation". The Cochrane Database of Systematic Reviews (2): CD003440. doi:10.1002/14651858.CD003440.pub4. PMID 24570145.
^Leeks KD, Hopkins DP, Soler RE, Aten A, Chattopadhyay SK; Task Force on Community Preventive Services (2010). "Worksite-based incentives and competitions to reduce tobacco use. A systematic review" (PDF). Am J Prev Med. 38 (2 Suppl): S263–74. doi:10.1016/j.amepre.2009.10.034. PMID 20117611.CS1 maint: Multiple names: authors list (link)
^ abWest R, Shiffman S (2007). Fast facts: smoking cessation (2nd ed.). Abingdon, England: Health Press Ltd. ISBN 978-1-903734-98-8.
^ abRigotti, NA; Clair, C; Munafò, MR; Stead, LF (16 May 2012). "Interventions for smoking cessation in hospitalised patients". The Cochrane Database of Systematic Reviews (5): CD001837. doi:10.1002/14651858.CD001837.pub3. PMC 4498489. PMID 22592676.
^ abThomsen, T; Villebro, N; Møller, AM (27 March 2014). "Interventions for preoperative smoking cessation". The Cochrane Database of Systematic Reviews (3): CD002294. doi:10.1002/14651858.CD002294.pub4. PMID 24671929.
^Caponnetto P; Russo C; Bruno CM; Alamo A; Amaradio MD; Polosa R. (March 2013). "Electronic cigarette: a possible substitute for cigarette dependence". Monaldi Archives for Chest Disease. 79 (1): 12–19. doi:10.4081/monaldi.2013.104. PMID 23741941.
^ abcdBaggett, Travis P.; Lebrun-Harris, Lydie A.; Rigotti, Nancy A. (November 2013). "Homelessness, Cigarette Smoking, and Desire to Quit: Results from a U.S. National Study". Addiction. 108 (11): 2009–2018. doi:10.1111/add.12292. ISSN 0965-2140. PMC 3797258. PMID 23834157.
^ abc"National Coalition for the Homeless". www.nationalhomeless.org. Retrieved 2017-06-29.
^Health, CDC's Office on Smoking and. "CDC - Fact Sheet - Adult Cigarette Smoking in the United States - Smoking & Tobacco Use". Smoking and Tobacco Use. Retrieved 2017-06-29.
^Baggett, Travis P.; Tobey, Matthew L.; Rigotti, Nancy A. (2013-07-18). "Tobacco Use among Homeless People — Addressing the Neglected Addiction". New England Journal of Medicine. 369 (3): 201–204. doi:10.1056/NEJMp1301935. ISSN 0028-4793. PMID 23863048.
^Pool, ER; Dogar, O; Lindsay, RP; Weatherburn, P; Siddiqi, K (13 June 2016). "Interventions for tobacco use cessation in people living with HIV and AIDS". The Cochrane Database of Systematic Reviews (6): CD011120. doi:10.1002/14651858.CD011120.pub2. PMID 27292836.
^Naqvi NH, Rudrauf D, Damasio H, Bechara A (2007). "Damage to the insula disrupts addiction to cigarette smoking". Science. 315 (5811): 531–4. Bibcode:2007Sci...315..531N. doi:10.1126/science.1135926. PMC 3698854. PMID 17255515.
^Lemmens, V; Oenema, A; Knut, IK; Brug, J (November 2008). "Effectiveness of smoking cessation interventions among adults: a systematic review of reviews". European Journal of Cancer Prevention. 17 (6): 535–44. doi:10.1097/cej.0b013e3282f75e48. PMID 18941375.
^King G, Yerger VB, Whembolua GL, Bendel RB, Kittles R, Moolchan ET (2009). "Link between facultative melanin and tobacco use among African Americans" (PDF). Pharmacol Biochem Behav. 92 (4): 589–96. doi:10.1016/j.pbb.2009.02.011. PMID 19268687. Archived from the original (PDF) on 2016-03-04. Retrieved 2012-09-12.
^Christakis NA, Fowler JH (2008). "The collective dynamics of smoking in a large social network". N Engl J Med. 358 (21): 2249–58. doi:10.1056/NEJMsa0706154. PMC 2822344. PMID 18499567.
^Park, EW; Tudiver, FG; Campbell, T (11 July 2012). "Enhancing partner support to improve smoking cessation". The Cochrane Database of Systematic Reviews (7): CD002928. doi:10.1002/14651858.CD002928.pub3. PMID 22786483.
^Peoples, Clayton D.; Sigillo, Alexandra E.; Green, Morgan; Miller, Monica K. (2012). "Friendship and Conformity in Group Opinions: Juror Verdict Change in Mock Juries". Sociological Spectrum. 32 (2): 178–193. doi:10.1080/02732173.2012.646163.
^Hitchman, SC; Fong, GT; Zanna, MP; Thrasher, JF; Laux, FL (December 2014). "The relation between number of smoking friends, and quit intentions, attempts, and success: findings from the International Tobacco Control (ITC) Four Country Survey". Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 28 (4): 1144–52. doi:10.1037/a0036483. PMC 4266625. PMID 24841185.
^American Cancer Society. "Guide to Quitting Smoking". www.cancer.org. Retrieved 6 July 2016.
^ abGlassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J (1990). "Smoking, smoking cessation, and major depression". JAMA. 264 (12): 1546–9. doi:10.1001/jama.1990.03450120058029. PMID 2395194.
^Condiotte MM, Lichtenstein E (1981). "Self-efficacy and relapse in smoking cessation programs". J Consult Clin Psychol. 49 (5): 648–58. doi:10.1037/0022-006X.49.5.648. PMID 7287974.
^Elfeddali, I; Bolman, C; Candel, MJ; Wiers, RW; De Vries, H (February 2012). "The role of self-efficacy, recovery self-efficacy, and preparatory planning in predicting short-term smoking relapse". British Journal of Health Psychology. 17 (1): 185–201. doi:10.1111/j.2044-8287.2011.02032.x. PMID 22107073.
^Shiffman S (1982). "Relapse following smoking cessation: a situational analysis". J Consult Clin Psychol. 50 (1): 71–86. doi:10.1037/0022-006X.50.1.71. PMID 7056922.
^ abLivingstone-Banks, J; Norris, E; Hartmann-Boyce, J; West, R; Jarvis, M; Hajek, P (13 February 2019). "Relapse prevention interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 2: CD003999. doi:10.1002/14651858.CD003999.pub5. PMC 6372978. PMID 30758045.
^Agboola, SA; Coleman, T; McNeill, A; Leonardi-Bee, J (July 2015). "Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials". Addiction. 110 (7): 1182–93. doi:10.1111/add.12941. PMID 25846123.
^ abcdefghijkKaiser Foundation Health Plan of the Northwest (2008). Cultivating Health: Freedom From Tobacco Kit. Kaiser Permanente. ISBN 978-0-9744864-8-2.[page needed]
^ abHughes JR, Stead LF, Lancaster T (2007). Hughes JR (ed.). "Antidepressants for smoking cessation". Cochrane Database Syst Rev (1): CD000031. doi:10.1002/14651858.CD000031.pub3. PMID 17253443.
^H.-J. Aubin; A. Farley; D. Lycett; P. Lahmek; P. Aveyard. (2012). "Weight gain in smokers after quitting cigarettes: meta-analysis". BMJ: British Medical Journal. 345 (345): e4439. doi:10.1136/bmj.e4439. PMC 3393785. PMID 22782848.
^Vanni H, Kazeros A, Wang R, Harvey BG, Ferris B, De BP, Carolan BJ, Hübner RH, O'Connor TP, Crystal RG (2009). "Cigarette smoking induces overexpression of a fat-depleting gene AZGP1 in the human". Chest. 135 (5): 1197–208. doi:10.1378/chest.08-1024. PMC 2679098. PMID 19188554.
^ abJo YH, Talmage DA, Role LW (2002). "Nicotinic receptor-mediated effects on appetite and food intake". J Neurobiol. 53 (4): 618–32. doi:10.1002/neu.10147. PMC 2367209. PMID 12436425.
^Klag MJ (1999). Johns Hopkins family health book. New York: HarperCollins. p. 86. ISBN 978-0-06-270149-7.
^Farley, Amanda C.; Hajek, Peter; Lycett, Deborah; Aveyard, Paul (2012-01-18). "Interventions for preventing weight gain after smoking cessation". The Cochrane Database of Systematic Reviews. 1: CD006219. doi:10.1002/14651858.CD006219.pub3. ISSN 1469-493X. PMID 22258966.
^Covey LS, Glassman AH, Stetner F (1997). "Major depression following smoking cessation". Am J Psychiatry. 154 (2): 263–5. doi:10.1176/ajp.154.2.263. PMID 9016279.
^Shahab, L; Andrew, S; West, R (January 2014). "Changes in prevalence of depression and anxiety following smoking cessation: results from an international cohort study (ATTEMPT)" (PDF). Psychological Medicine. 44 (1): 127–41. doi:10.1017/s0033291713000391. PMID 23507203.
^Borrelli B, Bock B, King T, Pinto B, Marcus BH (1996). "The impact of depression on smoking cessation in women". Am J Prev Med. 12 (5): 378–87. doi:10.1016/S0749-3797(18)30295-2. PMID 8909649.
^Máirtín S. McDermott; Theresa M. Marteau; Gareth J. Hollands; Matthew Hankins; Paul Aveyard. "Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study". BJP.
^American Cancer Society. "Benefits of Quitting Smoking Over Time". www.cancer.org. Retrieved 22 July 2016.
^Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000). "Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies". BMJ. 321 (7257): 323–9. doi:10.1136/bmj.321.7257.323. PMC 27446. PMID 10926586.
^ abDoll R, Peto R, Boreham J, Sutherland I (2004). "Mortality in relation to smoking: 50 years' observations on male British doctors". BMJ. 328 (7455): 1519. doi:10.1136/bmj.38142.554479.AE. PMC 437139. PMID 15213107.
^Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group (2005). "The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial". Annals of Internal Medicine. 142 (4): 233–9. doi:10.7326/0003-4819-142-4-200502150-00005. PMID 15710956.CS1 maint: Multiple names: authors list (link)
^Taghizadeh, N; Vonk, JM; Boezen, HM (7 April 2016). "Lifetime Smoking History and Cause-Specific Mortality in a Cohort Study with 43 Years of Follow-Up". PLOS ONE. 11 (4): e0153310. Bibcode:2016PLoSO..1153310T. doi:10.1371/journal.pone.0153310. PMC 4824471. PMID 27055053.
^Mills, E; Eyawo, O; Lockhart, I; Kelly, S; Wu, P; Ebbert, JO (February 2011). "Smoking cessation reduces postoperative complications: a systematic review and meta-analysis". The American Journal of Medicine. 124 (2): 144–154.e8. doi:10.1016/j.amjmed.2010.09.013. PMID 21295194.
^Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T (1997). "Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation". JAMA. 278 (21): 1759–66. doi:10.1001/jama.278.21.1759. PMID 9388153.
^Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MP (2010). "Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD". Thorax. 65 (8): 711–8. doi:10.1136/thx.2009.131631. PMID 20685746.
^Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, Hiscock R (2011). "One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services". Nicotine Tob Res. 13 (2): 135–45. doi:10.1093/ntr/ntq222. PMID 21196451.
^Schiaffino A, Fernández E, Kunst A, Borrell C, García M, Borràs JM, Mackenbach JP (2007). "Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000)". Prev Med. 45 (2–3): 226–32. doi:10.1016/j.ypmed.2007.05.009. PMID 17604832.
^Fowkes FJ, Stewart MC, Fowkes FG, Amos A, Price JF (2008). "Scottish smoke-free legislation and trends in smoking cessation". Addiction. 103 (11): 1888–95. doi:10.1111/j.1360-0443.2008.02350.x. PMID 19032538.
^Federico B, Costa G, Ricciardi W, Kunst AE (2009). "Educational inequalities in smoking cessation trends in Italy, 1982–2002". Tob Control. 18 (5): 393–8. doi:10.1136/tc.2008.029280. PMID 19617220.
^Zuo, Xiaoan; Zhao, Halin; Zhao, Xueyong; Guo, Yirui; Yun, Jianying; Wang, Shaokun; Miyasaka, Takafumi (2009). "Cigarette smoking among adults and trends in smoking cessation - United States, 2008". MMWR Morb Mortal Wkly Rep. 58 (44): 1227–32. PMID 19910909.
^Qian J, Cai M, Gao J, Tang S, Xu L, Critchley JA (2010). "Trends in smoking and quitting in China from 1993 to 2003: National Health Service Survey data". Bull World Health Organ. 88 (10): 769–76. doi:10.2471/BLT.09.064709. PMC 2947036. PMID 20931062.
^Martin, Anya (May 13, 2010). "What it takes to quit smoking". MarketWatch. Dow Jones. p. 2. Retrieved May 14, 2010.
^Health, CDC's Office on Smoking and. "CDC - Fact Sheet - Adult Cigarette Smoking in the United States - Smoking & Tobacco Use". Smoking and Tobacco Use. Retrieved 21 July 2016.
Wikimedia Commons has media related to Smoking cessation.
Jason Wright (2013). Knowing How To Quit Smoking. 1. p. 38. ISBN 978-1494238452.
Henningfield J, Fant R, Buchhalter A, Stitzer M (2005). "Pharmacotherapy for nicotine dependence". CA Cancer J Clin. 55 (5): 281–99, quiz 322–3, 325. doi:10.3322/canjclin.55.5.281. PMID 16166074.
Hughes JR, Keely J, Naud S (2004). "Shape of the relapse curve and long-term abstinence among untreated smokers". Addiction. 99 (1): 29–38. doi:10.1111/j.1360-0443.2004.00540.x. PMID 14678060.
Hutter H, Moshammer H, Neuberger M (2006). "Smoking cessation at the workplace: 1 year success of short seminars". Int Arch Occup Environ Health. 79 (1): 42–8. doi:10.1007/s00420-005-0034-y. PMID 16133522.
Marks DF (2005). Overcoming your smoking habit: a self-help guide using cognitive behavioral techniques. London: Robinson. ISBN 978-1-84529-067-2.
Peters MJ, Morgan LC (2002). "The pharmacotherapy of smoking cessation". Med J Aust. 176 (10): 486–90. PMID 12065013.
West R (2006). "Tobacco control: present and future". Br Med Bull. 77–78 (1): 123–36. doi:10.1093/bmb/ldl012. PMID 17106058.
McFarland JW, Folkenberg EJ (1964). How to stop smoking in five days(PDF). Englewood Cliffs, NJ: Prentice-Hall. Archived from the original (PDF) on 2015-02-13.
Chief Medical Officer
Globalization and disease
Health care reform
Public health law
Public health intervention
Public health laboratory
Sociology of health and illness
Occupational safety and health
Human factors and ergonomics
Health impact assessment
Open-source healthcare software
Public health informatics
Social determinants of health
Race and health
Biological and epidemiological statistics
Randomized controlled trial
Statistical hypothesis testing
Analysis of variance (ANOVA)
Infectious and epidemic disease prevention
Public health surveillance
Sexually transmitted infection
Food hygiene and safety management
Genetically modified food
Good agricultural practice
Good manufacturing practice
Health behavioral sciences
Diffusion of innovations
Health belief model
Social cognitive theory
Social norms approach
Theory of planned behavior
Organizations, education and history
Centre for Disease Prevention and Control
Committee on the Environment, Public Health and Food Safety
Ministry of Health and Family Welfare
Centers for Disease Control and Prevention
City and county health departments
Council on Education for Public Health
Public Health Service
World Health Organization
World Toilet Organization
Bachelor of Science in Public Health
Doctor of Public Health
Professional degrees of public health
Schools of public health
Sara Josephine Baker
Samuel Jay Crumbine
Carl Rogers Darnall
Germ theory of disease
Social hygiene movement
Country and region
Western Europe and North America
Smoking in Jewish law
Health effects of tobacco (Nicotine poisoning
Prevalence of tobacco use
Schizophrenia and smoking
Smokeless tobacco keratosis
Smoking and male infertility
Tobacco packaging warning messages
WHO Framework Convention on Tobacco Control
Protocol to Eliminate Illicit Trade in Tobacco Products
World No Tobacco Day
Women and smoking
Ptosis of the breast
Smoking and female infertility
Smoking and pregnancy
List of smoking bans
Smoking bans in private vehicles
Tobacco-Free College Campuses
Country and region
Cigarette consumption per capita
History of smoking
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
This paper describes two phases of formative research that had the goal of developing a treatment designed to improve adherence with the nicotine patch in HIV-positive Latino smokers. Each research phase (Phase I and II) was conducted independent of the other and used different qualitative methods t
Supplemental nicotine preloading for smoking cessation in posttraumatic stress disorder: Results from a randomized controlled trial.
Dennis PA1, Kimbrel NA2, Dedert EA1, Beckham JC2, Dennis MF1, Calhoun PS3.
Addictive behaviors.Addict Behav.2016 Aug;59:24-9. doi: 10.1016/j.addbeh.2016.03.004. Epub 2016 Mar 11.
BACKGROUND: Individuals with posttraumatic stress disorder (PTSD) are more likely to smoke and more likely to relapse following a quit attempt than individuals without PTSD. Thus, there is a significant need to study promising interventions that might improve quit rates for smokers with PTSD. One su
Addictive behaviors.Addict Behav.2016 Aug;59:30-4. doi: 10.1016/j.addbeh.2016.03.009. Epub 2016 Mar 19.
INTRODUCTION: Up to 75% of people with serious mental illness (SMI) smoke, and most are highly dependent on nicotine, consuming more cigarettes per day than smokers without mental illness. Even with evidence-based treatment, relapses are common, resulting in high morbidity and early mortality from t
CDC Vital Signs: Adult Smoking among People with Mental Illness (Centers for Disease Control and Prevention) Available in Spanish Complementary Health Approaches for Smoking Cessation: What the Science Says (National ...
The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health ...